Types segment classifies Valsartan Dispersible Tablets by dosage strength and origin (branded versus generic). The 80 mg strength dominates, representing roughly 55 % of unit sales, because it aligns with the most common therapeutic dose for hypertension and heart failure. The 40 mg variant accounts for 30 %, primarily prescribed for dose titration in elderly or renal‑impaired patients. The 160 mg tablet, used in combination regimens, contributes the remaining 15 %. Within each strength, branded products retain a premium share—approximately 35 % of the 80 mg volume—driven by perceived quality and physician preference, while generics occupy the balance, exerting price pressure that compresses overall market margins. Regulatory pathways for each strength differ; the 80 mg and 40 mg tablets have established monographs, facilitating faster approval for generics, whereas the 160 mg strength often requires additional bioequivalence studies due to its higher dose, extending time‑to‑market. Consequently, the 160 mg segment exhibits a higher proportion of branded products, which sustains a modest premium despite lower volume. This type‑based taxonomy clarifies how formulation choices and brand positioning affect the Valsartan Dispersible Tablets market size, informing manufacturers’ portfolio optimization and capacity planning.
